NanoViricides, Inc.
135 Wood Street
Suite 205
West Haven
Connecticut
06516
United States
Website: http://www.nanoviricides.com/
Email: info@nanoviricides.com
351 articles about NanoViricides, Inc.
-
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
2/15/2024
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securities and Exchange Commission on Wednesday, February 14, 2024.
-
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
1/29/2024
NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported that the healthy subjects part of the Phase 1a/1b Clinical Trial of NV-CoV-2 was completed successfully.
-
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
11/15/2023
NanoViricides, Inc. (NYSE American: NNVC ) reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2023 with the Securities and Exchange Commission (SEC) on Tuesday, November 14, 2023.
-
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
11/14/2023
NanoViricides, Inc. reports that its broad-spectrum antiviral drug candidate, NV-387 was highly effective in an animal model that is used in drug development for MPox and Smallpox virus infections in humans.
-
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
10/16/2023
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission on Friday, October 13, 2023.
-
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
10/12/2023
NanoViricides, Inc announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston, MA, on October 16, 2023 at 6:07pm ET in Track 2B.
-
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
8/21/2023
NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, is progressing successfully.
-
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
7/11/2023
NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV.
-
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
7/6/2023
NanoViricides, Inc. reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.
-
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
6/29/2023
NanoViricides, Inc. reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.
-
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
5/31/2023
NanoViricides, Inc., announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET.
-
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
5/16/2023
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.
-
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
5/4/2023
NanoViricides, Inc., a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which will be held on May 10-11, 2023, at the Plaza Hotel in the heart of New York City.
-
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
4/25/2023
NanoViricides, Inc. reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate.
-
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
4/17/2023
NanoViricides, Inc., a clinical stage global leader in nanomedicines against viruses, announced that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India.
-
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
4/4/2023
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer").
-
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
2/15/2023
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission on Tuesday, February 14, 2023.
-
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
1/4/2023
NanoViricides, Inc. announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech Showcase 2023 Conference in San Fransisco on Monday, January 9th at 10:30pm PT.
-
NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET
12/5/2022
NanoViricides, Inc. announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET.
-
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
10/14/2022
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission on Thursday, October 13, 2022.